In a bid to bolster its pipeline, AbbVie has partnered with Sosei Heptares to develop and commercialise small molecules that modulate new G protein-coupled receptor (GPCR) targets associated with neurological disease. The deal, which is worth up to US$1.2 B, provides AbbVie with access to Sosei’s StaR® (Stabilised Receptor) technology and structure-based drug design platform. Interestingly, the deal marks the second agreement between the two companies, who previously collaborated in June 2020, for the development of new molecules targeting inflammatory and autoimmune diseases.